episode, Dr. Arellano addresses current treatment and treatment advances for AML, including stem cell transplantation and cellular therapy. She also explains the goal and impact of the Beat AML Master Trial, a groundbreaking collaborative and targeted clinical trial for patients with AML. Transcript: Alicia: Welcome to The Bloodline with LLS. I ...

Atlanta, Georgia. On this episode, Dr. Arellano defines acute myeloid leukemia (AML) and how it is diagnosed. She addresses questions about cause and prevention and how treatment is determined for younger vs older patients. Dr. Arellano also explains the importance of a patient getting a second opinion to not only increase their education

2025年3月17日 · Ashkan Emadi, MD, PhD, discusses how the combination of venetoclax plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.

Episode: ‘Visions of Hope: Continuing to Beat AML’ Description: The fight to effectively treat and cure the complex disease of acute myeloid leukemia (AML) continues. In this episode, we speak to Dr. Elie Traer, Dr. Karin Rodland and Dr. Lee Greenberger about an exciting new study for AML. The doctors share about a longtime collaboration

2023年12月8日 · Issa explains that acute myeloid leukemia (AML) classification relies more on mutations and cytogenetics rather than cell types involved. Previously, subtypes were defined by phenotype (monocytic, megakaryocytic). While cell phenotype has some relevance for clinical trials, major classification now uses genetic and chromosomal abnormalities.

2023年6月22日 · At our center, we obtain the diagnosis of AML through morphology and flow cytometry, probably within 24 hours of a patient presentation. But we then wait for the cytogenetic results as well as, importantly, the mutational results before selecting therapy.

2024年10月2日 · Episode 117: AML Series, Pt. 3 - AML Induction: Definitions and Overview In this week’s episode, we start our three-part discussion on AML induction, this week focusing on key definitions and an overview of treatment. Also, if you have not done so, please do check out our hemepath series

Episode 115: AML Series, Pt. 1 - CHIP, CCUS, ICUS, oh my! This week, we kick off a new series focusing on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this first episode, we discuss the alphabet soup of premalignant hematologic conditions including CHIP, CCUS, and ICUS, before moving onto MDS and AML in future episodes.

2024年11月13日 · What is the data behind the use of hypomethylating agents (HMAs) in the maintenance setting for AML? Researchers knew that hypomethylating agents (e.g. azacitidine and decitabine) were effective in treating AML in older adults and in the refractory setting, so these agents were studied as maintenance options

2023年3月21日 · The drug seems to be showing promise in p53-mutated AML [acute myeloid leukemia] and MDS. There was an abstract track looking at its triple combination, and that’s another thing we’ve been ...